Fruquintinib A new arrow in the quiver for metastatic colorectal cancer care

One of the main causes of the worldwide cancer burden is Colorectal Cancer (CRC), and thanks to the development of new drugs and the growing number of patients receiving local treatments and the best supportive care, considerable advancements have been made in survival. However, the prognosis for patients resistant to fluoropyrimidines, irinotecan, oxaliplatin and target therapies is dismal, highlighting the urgent need for the research and application of new treatment options.